about
In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIVMinority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacyCharacterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor.The maraviroc expanded access program - safety and efficacy data from an open-label study.Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysisOnce-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment.First prospective comparison of genotypic vs phenotypic tropism assays in predicting virologic responses to Maraviroc (MVC) in a phase 3 study: MODERN.Efficacy and safety of lersivirine versus etravirine for the treatment of HIV-1 infection in patients with prior non-nucleoside reverse transcriptase inhibitor (NNRTI) use and evidence of NNRTI resistance: a randomized phase 2B trial.Pharmacokinetics, Safety, and Efficacy of Maraviroc in Treatment-Experienced Pediatric Patients Infected With CCR5-Tropic HIV-1.Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection.Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study.Population and ultra-deep sequencing for tropism determination are correlated with Trofile ES: genotypic re-analysis of the A4001078 maraviroc study.Efficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced HIV-1-infected patients (CAL30001 Study).Efficacy and Safety of Lersivirine (UK-453,061) versus Efavirenz in Antiretroviral Treatment-Naïve HIV-1-Infected PatientsInfluence of amount and percentage of CXCR4-using virus in predicting week 48 responses to maraviroc in treatment-naïve patientsThe development of resistance of HIV-1 to zalcitabineHIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapyRare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimenIncidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials
P50
Q24672993-3B3CE9A7-7C74-4EDA-8EFB-F994E769CC80Q28473296-5B3B824B-795B-42AD-B1C7-CB53E4485335Q30378764-DA10EFDD-F3D5-44F8-8D37-5AB25EDD5D78Q30911112-E81A7CED-FC33-42A8-94FA-1D4D7856BC6AQ33988153-A21D1C90-FE77-4A7D-A96A-25716E1C748EQ36868170-DF1632B5-3921-4B3F-B34E-05883C3B730CQ41664011-3F9A29B2-14DD-4C33-9620-EE6EBB9D002CQ41686484-2E7DD6C7-58E4-4ADC-A4B5-B35D656A2C7DQ42696471-93B41DA2-D3E0-4B99-ABA2-E1EA8C923ED7Q43683306-D6B160C1-93BC-4653-A9FB-A1FB8F0542A2Q46375651-84727652-FF6B-4685-A5FC-C381626348D0Q46697227-ACB53D3B-49F3-4BB1-90FB-30AFAF7F9096Q51942612-21E9F0FE-26C6-4C25-B51B-E7E5D8559F13Q58192245-0B3739DA-64DD-423D-9496-2AE933C0B23FQ59255334-398DF84A-9DB3-4F48-92B1-63EC5FECE070Q73331361-D4AA5761-6E8A-4CA6-9C0A-10D21E307744Q77386253-3773D8FE-C503-46B1-B928-82BA216C9161Q79800619-99057FA5-5454-48E7-830B-6CA91214D188Q92126842-8551D497-D47D-45A5-ADAB-53914DEF1DAE
P50
description
researcher ORCID ID = 0000-0003-3276-9925
@en
wetenschapper
@nl
name
Charles Craig
@ast
Charles Craig
@de
Charles Craig
@en
Charles Craig
@es
Charles Craig
@nl
type
label
Charles Craig
@ast
Charles Craig
@de
Charles Craig
@en
Charles Craig
@es
Charles Craig
@nl
prefLabel
Charles Craig
@ast
Charles Craig
@de
Charles Craig
@en
Charles Craig
@es
Charles Craig
@nl
P106
P21
P31
P496
0000-0003-3276-9925